Want to see SG:569 full AI Analyst Report?
Top Page
VicPlas International Ltd.
(SGX:569)
Select Model
Select Model
Rating:44Neutral
Price Target:
S$0.07
▼(-7.14% Downside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by weak financial quality: despite a strong 2025 revenue rebound and healthy gross margins, recent losses, sharply reduced operating cash flow, and negative free cash flow weigh heavily. Technical indicators are broadly neutral with some short-term momentum, but the longer-term trend remains below key moving averages. Valuation is difficult to support given the negative P/E and lack of dividend yield data.
Positive Factors
2025 Revenue Rebound
The sharp 2025 top-line recovery indicates renewed demand or improved commercial execution. If sustained, higher revenue can improve operating leverage and provide a stronger base for restoring profitability over the next several reporting periods.
Negative Factors
Persistent Net Losses
Recent revenue growth has not yet translated into positive bottom-line earnings. Continued losses weaken retained capital and indicate that operating costs or other charges remain too high for the current revenue base, limiting earnings durability.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 Revenue Rebound
The sharp 2025 top-line recovery indicates renewed demand or improved commercial execution. If sustained, higher revenue can improve operating leverage and provide a stronger base for restoring profitability over the next several reporting periods.
Read all positive factors
VicPlas International Ltd. (569) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$34.24M
Dividend YieldN/A
Average Volume (3M)97.25K
Price to Earnings (P/E)―
Beta (1Y)0.42
Revenue Growth17.24%
EPS Growth-353.85%
CountrySG
Employees702
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding511,537,700
10 Day Avg. Volume66,350
30 Day Avg. Volume97,253
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.65
Price to Sales (P/S)0.38
P/FCF Ratio-7.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VicPlas International Ltd. Business Overview & Revenue Model
Company Description
Vicplas International Ltd, established in Singapore in 1993, operates as an investment holding company with key business segments in medical devices and piping systems. The company's geographical reach includes Singapore, Malaysia, the People's Re...
VicPlas International Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 126.34M | 120.81M | 102.39M | 129.22M | 130.81M | 113.94M |
| Gross Profit | 42.11M | 66.57M | 52.42M | 66.19M | 68.06M | 60.84M |
| EBITDA | 4.35M | 7.01M | 6.93M | 13.18M | 17.93M | 19.03M |
| Net Income | -6.04M | -2.36M | -1.36M | 4.24M | 8.84M | 10.40M |
Balance Sheet | ||||||
| Total Assets | 136.02M | 137.71M | 131.49M | 119.02M | 130.34M | 111.66M |
| Cash, Cash Equivalents and Short-Term Investments | 6.51M | 4.71M | 4.97M | 8.57M | 8.89M | 9.87M |
| Total Debt | 43.91M | 41.11M | 32.47M | 17.55M | 28.01M | 19.57M |
| Total Liabilities | 67.51M | 66.32M | 56.93M | 40.46M | 52.03M | 40.01M |
| Stockholders Equity | 68.51M | 71.39M | 74.57M | 78.56M | 78.31M | 71.64M |
Cash Flow | ||||||
| Free Cash Flow | -2.89M | -5.99M | -7.82M | 12.53M | -2.61M | 3.83M |
| Operating Cash Flow | 1.96M | 388.00K | 6.72M | 17.88M | 10.25M | 9.01M |
| Investing Cash Flow | -632.00K | -6.36M | -14.53M | -5.10M | -12.79M | -5.16M |
| Financing Cash Flow | -2.64M | 5.75M | 4.24M | -12.76M | 1.63M | 1.86M |
VicPlas International Ltd. Technical Analysis
Negative
0.07
Price Trends
0.08
Negative
0.08
Negative
0.09
Negative
Market Momentum
>-0.01
Positive
39.51
Neutral
20.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:569, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.51 is Neutral, neither overbought nor oversold. The STOCH value of 20.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:569.
VicPlas International Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
SG:569
VicPlas International Ltd.
0.07
-0.02
-20.24%
SG:505
Asiamedic Limited
0.02
<0.01
20.00%
SG:546
Medtecs International Corporation Ltd.
0.11
-0.01
-8.80%
SG:584
AJJ Medtech Holdings Limited
0.01
0.00
0.00%
SG:MIJ
Alliance Healthcare Group Ltd.
0.18
0.05
43.65%
SG:OTX
Medinex Ltd.
0.23
0.03
16.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.